Operating Income - Zhejiang Ausun Pharmaceutical Co Ltd (SSE:603229) - Alpha Spread

Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229

Watchlist Manager
Zhejiang Ausun Pharmaceutical Co Ltd Logo
Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229
Watchlist
Price: 6.59 CNY -2.37% Market Closed
Market Cap: 5.5B CNY
Have any thoughts about
Zhejiang Ausun Pharmaceutical Co Ltd?
Write Note

Zhejiang Ausun Pharmaceutical Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zhejiang Ausun Pharmaceutical Co Ltd
Operating Income Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang Ausun Pharmaceutical Co Ltd
SSE:603229
Operating Income
ÂĄ298.4m
CAGR 3-Years
23%
CAGR 5-Years
50%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Income
ÂĄ2.6B
CAGR 3-Years
-2%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Operating Income
ÂĄ3.4B
CAGR 3-Years
17%
CAGR 5-Years
20%
CAGR 10-Years
22%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Operating Income
ÂĄ5.8B
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Operating Income
ÂĄ4B
CAGR 3-Years
-1%
CAGR 5-Years
14%
CAGR 10-Years
3%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Operating Income
-ÂĄ749.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Zhejiang Ausun Pharmaceutical Co Ltd's Operating Income?
Operating Income
298.4m CNY

Based on the financial report for Jun 30, 2024, Zhejiang Ausun Pharmaceutical Co Ltd's Operating Income amounts to 298.4m CNY.

What is Zhejiang Ausun Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
50%

Over the last year, the Operating Income growth was 22%. The average annual Operating Income growth rates for Zhejiang Ausun Pharmaceutical Co Ltd have been 23% over the past three years , 50% over the past five years .

Back to Top